SX-682

DB19210InvestigationalSmall molecule

SX-682 is under investigation in clinical trial NCT04574583 (Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With Bintrafusp Alfa (M7824 or Tgf-beta...

Formula / weight: C₁₉H₁₄BF₄N₃O₄S · 467.2 g/mol (avg)
Also known as: 2-(2-dihydroxyboryl-5-trifluoromethoxybenzylsulfanyl)pyrimidine-5-carboxylic acid (4-fluorophenyl)amide · Boronic acid, b-(2-(((5-(((4-fluorophenyl)amino)carbonyl)-2-pyrimidinyl)thio)methyl)-4-(trifluoromethoxy)phenyl)-
Code names: SX-682

Resolves to

Compound

UNIIH5212R2DPMCAS1648843-04-2ChEMBLCHEMBL4297480

Structure

InChIKeySDUDZBCEHIZMFZ-UHFFFAOYSA-NSMILESOB(O)C1=CC=C(OC(F)(F)F)C=C1CSC1=NC=C(C=N1)C(=O)NC1=CC=C(F)C=C1

Targets

P25025CXCR2P25024CXCR1

What you can answer from here — as of April 23, 2025

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

13Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with SX-682, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account